MO3-10-3Sustained fever associated with immune checkpoint inhibitors may be a poor prognostic factor

Abstract Immune-checkpoint inhibitors (ICIs) have been established as novel standard treatment for various types of malignancies, and immune-related adverse events (irAEs) are frequently observed with ICIs. This study aimed to evaluate whether fever associated with ICIs correlates with treatment response or prognosis. We conducted a retrospective study of patients who received anti PD-1antibody monotherapy at Wakayama Medical University hospital (n = 188). Fever was classified as transient fever related to irAE and infection and sustained fever from onset of ICI administration. Sustained fever was observed in 10 out of 188 people (5.3%), and all cases were controlled with Acetaminophen or Naproxen. All patients with sustained fever and had high tumor burden and Performance Status 1 or 2. In 7 of 10 patients, PS decreased rapidly after ICI administration and the second cycle was discontinued and died within 3 months. Three out of ten cases were able to continue, three patients were both effective, fever disappeared and antipyretics were also stopped. Our data suggest that Sustained fever after ICI administration was considered to be a poor prognostic factor unless response.